Windward Bio
48 employees on LinkedIn · 10 known investors
Find your way into Windward Bio
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases. Its lead program WIN378 is an ultra long-acting anti-TSLP antibody in a Phase 2/3 asthma trial and Phase 2 COPD study, with a broader pipeline including the anti-TSLPxIL-13 bispecific WIN027.
Investors · 10
OrbiMedNew York · $1M – $75M
Quan CapitalShanghai
RA CapitalBoston
Sanofi VenturesCambridge · $5M
SR One Capital ManagementRedwood City
Janus Henderson InvestorsreportedLondon
Novo HoldingsreportedCopenhagen · $1.1M – $54M
Pivotal Life SciencesreportedSan Francisco
Qiming Venture PartnersreportedBeijing · $5M – $134M
RTW Investments L.P.reportedNew York
Funding
SEC filings, press & company announcements- Undisclosed amountCrossoverMay 2026Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Windward Bio do?
- Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases. Its lead program WIN378 is an ultra long-acting anti-TSLP antibody in a Phase 2/3 asthma trial and Phase 2 COPD study, with a broader pipeline including the anti-TSLPxIL-13 bispecific WIN027.
- Who are Windward Bio's investors?
- Windward Bio's investors include OrbiMed, Quan Capital, RA Capital, Sanofi Ventures, SR One Capital Management, Janus Henderson Investors, Novo Holdings, Pivotal Life Sciences and 2 more.